# Razor

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/razor

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.occamzrazor.com
- Total disclosed funding: $4.5M
- Latest round: Seed (May 1, 2019)
- Investors on record: 3

## About

Based in NY, US, and founded in 2015, Razor, inc trading as OccamzRazor develops machine learning methods to improve the success of Parkinson's disease drug discovery and development. In March 2022, Razor, inc raised USD 6.1 million in venture funding led by an individual investor including Lauder Partners, re. Mind Capital, and Valor Equity Partners. Katharina Sophia Volz (CEO) and Martin Bringmann (CSO) are the co-founders of the company.

The company focuses on the discovery and development of modality agnostic treatments for complex diseases of brain aging. OccamzRazor’s platform identifies disease targets and mechanisms and it supercharges human scientific reasoning through machine learning. 

The firm develops the insight prediction pipeline that allows to automatically draw knowledge from millions of peer-reviewed publications, proprietary datasets, clinical trial findings, and own lab experiments. The company partners with UAB, Axxam Neuroscience CRO, The Neuroscience Research Institute, and more.

The organization plans to use the March 2022 funding to launch its discovery pipeline and advance preclinical development in Parkinson’s.

## Funding rounds

- Seed, May 1, 2019, $4.5M — Techammer, Bioverge, Human Capital

## Investors

- Techammer — Seed
- Bioverge (https://capitalatlas.ai/funds/bioverge) — Seed
- Human Capital (https://capitalatlas.ai/funds/human-capital) — Seed